reports
Savara Announces New Employment Inducement Grant
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees. On December 20, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to five new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 100,000 shares of the Company’s common stock and restricted stock units (RSUs) covering an aggregate of 100,000 shares of the Company’s common stock. These equity...
Savara Initiates Rolling Submission of a Biologics License Application...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, initiated a rolling submission of a BLA to the FDA for MOLBREEVI for the potential treatment of aPAP, a chronic and debilitating rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. MOLBREEVI was granted Fast Track and Breakthrough Therapy Designations in 2019 for the treatment of patients with aPAP. As a result, the Company is allowed to submit individual modules of the BLA as they are completed rather th...
Savara Announces Participation in the 43rd Annual J.P. Morgan Healthca...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company will present and host 1x1 meetings at the 43rd Annual J.P. Morgan Healthcare Conference. Date/Time of Presentation: January 15, 5:15pm PT/8:15pm ET Presenter: Matt Pauls, Chair and Chief Executive Officer, Savara Location: Westin St. Francis, San Francisco, Elizabethan C Room The live webcast and subsequent replay will be available on the “Events & Presentations” section of the Company’s corporate website at and will...
- Jonathan Moreland
RMAX RE/MAX HOLDINGS INC.
PSEC PROSPECT CAPITAL CORPORATION
PPSI PIONEER POWER SOLUTIONS
PBF PBF ENERGY INC. CLASS A
OPK OPKO HEALTH INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
MPAA MOTORCAR PARTS OF AMERICA INC.
GLP GLOBAL PARTNERS LP
EL ESTEE LAUDER COMPANIES INC. CLASS A
APPS DIGITAL TURBINE
ACRS ACLARIS THERAPEUTICS INC.
MEDP MEDPACE HOLDINGS INC.
ENPH ENPHASE ENERGY INC.
HTLD HEARTLAND EXPRESS INC.
RAIL FREIGHTCAR AMERICA INC.
SVRA SAVARA
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
ANGI ANGI INC. CLASS A
SNBR SLEEP NUMBER CORPORATION
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
MBIN MERCHANTS BANCORP
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
NOVA SUNNOVA ENERGY INTERNATIONAL
GRWG GROWGENERATION
PCB PACIFIC CITY FINANCIAL CORP
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
ONEW ONEWATER MARINE
BDSX BIODESIX
CSU CAPITAL SENIOR LIVING
MODV MODIVCARE INC
GRNT GRANIT SKOPKE
UAN CVR PARTNERS LP
INBX INHIBRX
OSCR INC.
WOLF OSCAR HEALTH
CLVT WOLFSPEED INC
ZETA CLARIVATE PLC
RWAY ZETA GLOBAL HLDGS CORP
CGBD RUNWAY GROWTH FINANCE CORP
NXGL TCG BDC
BIGZ INC.
DOUG NEXGEL INC
KLG_w BLACKROCK INNOVATION AND GROWTH TST
EP DOUGLAS ELLIMAN INC
MIO WK KELLOGG CO
MDRR EMPIRE PETROLEUM CORP
BNTC PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
EVM MEDALIST DIVERSIFIED REIT INC.
FGF BENITEC BIOPHARMA INC
EATON VANCE INSD CALIF MUN BD FD
FG FINANCIAL GROUP
INC.
Savara Announces New Employment Inducement Grant
LANGHORNE, Pa.--(BUSINESS WIRE)-- . (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to four new employees. On November 20, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 80,000 shares of the Company’s common stock and restricted stock units (RSUs) covering an aggregate of 70,000 shares of the Company’s common stock. These equity ...
Savara Announces Encore Presentation of Results from the Phase 3 IMPAL...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that an encore presentation of results from the pivotal, Phase 3 IMPALA-2 trial will be presented at the British Thoracic Society (BTS) Winter Meeting, taking place November 27-29, 2024, in London, England. BTS Platform Presentation Details Title: “Inhaled Molgramostim Improves Pulmonary Gas Exchange and Respiratory Health-Related Quality of Life in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results from IMPALA-...
Savara Inc: 1 director
A director at Savara Inc bought 100,000 shares at 2.876USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
- Jonathan Moreland
PPSI PIONEER POWER SOLUTIONS
NMFC NEW MOUNTAIN FINANCE CORPORATION
MPAA MOTORCAR PARTS OF AMERICA INC.
GLP GLOBAL PARTNERS LP
RAIL FREIGHTCAR AMERICA INC.
SVRA SAVARA
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
SMRT SMARTSPACE SOFTWARE
SNBR SLEEP NUMBER CORPORATION
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
PCB PACIFIC CITY FINANCIAL CORP
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
REYN REYNOLDS CONSUMER PRODUCTS INC.
UAN CVR PARTNERS LP
OSCR OSCAR HEALTH
ZETA ZETA GLOBAL HLDGS CORP
BGS B&G FOODS
EP INC.
MIO EMPIRE PETROLEUM CORP
MDRR PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
EVM MEDALIST DIVERSIFIED REIT INC.
ACMR EATON VANCE INSD CALIF MUN BD FD
A.C. MOORE ARTS & CRAFTS
INC.
Savara Announces Participation in Upcoming Healthcare Conferences
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will be attending the below listed upcoming healthcare conferences and participating in fireside chats. Jefferies London Healthcare Conference, November 19-21, 2024 Fireside Chat: November 20th, 1:00pm GT/8:00am ET/5:00am PT Piper Sandler 36th Annual Healthcare Conference, December 3-5, 2024 Fireside Chat: December 3rd, 8:30am ET/5:30am PT The live webcasts and subsequent replays will be available...
Savara Reports Third Quarter 2024 Financial Results and Provides Busin...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2024 and provided a business update. “After a productive pre-BLA meeting with the FDA, we are working diligently to initiate a rolling submission for MOLBREEVI by the end of this year, with plans to complete the BLA submission by the end of 1Q 2025—thus enabling a potential approval in the U.S. by the end of 2025, if priority review is granted,” said Matt Pauls, Chair and CEO, Sa...
Savara to Present at the Guggenheim Inaugural Healthcare Innovation Co...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Guggenheim Inaugural Healthcare Conference on November 12, 2024 at 10:00am PT/1:00pm ET. A live webcast and subsequent replay of the fireside chat will be available on Savara's website at and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim inhalation sol...
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar ...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that a new episode of The Balancing Act®, sponsored by Savara and featuring autoimmune Pulmonary Alveolar Proteinosis (aPAP), is airing on Lifetime TV’s Behind the Mystery™ a recurring series on The Balancing Act® television show devoted to advocating for people with rare and genetic diseases. The episode centers on the diagnostic journey of an aPAP patient and includes insights from Bruce Trapnell, M.D., Professor of Medicine and Pediatrics, U...
Savara Announces New Employment Inducement Grant
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to four new employees. On October 17, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 95,000 shares of the Company’s common stock and restricted stock units (RSUs) covering an aggregate of 95,000 shares of the Company’s common stock. These equity awa...
Savara Announces Patient Journey Map for People Living with Autoimmune...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of an abstract for poster presentation at the CHEST 2024 Annual Meeting, taking place October 6-9 in Boston. The Company is also sponsoring an Industry Symposium at the meeting. Details are as follows: Accepted Abstract Title: “A Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)” Poster Session: Diffuse Lung Disease Abstracts Posters (D) Date and Time: October 8, 2024, 1:45 - 2:30pm ...
Savara Announces New Employment Inducement Grant
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On September 25, 2024, Savara's Board of Directors granted the inducement awards to Braden Parker, who joined the Company as Chief Commercial Officer on September 24, 2024. The inducement awards consist of options to purchase 170,000 shares of the Company’s common stock and restricted stock units (RSUs) covering 85,000 shares of the Company’s common stock. These equity awards were granted under the...
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhala...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the Savara Early Access Program, a molgramostim Expanded Access Program (EAP) for patients with aPAP. The program enables physicians to request molgramostim for eligible aPAP patients in select geographies where the product is not commercially available and in compliance with local regulatory requirements. The Savara Early Access Program has been reviewed and allowed to proceed by the U.S. Food and Drug Administration (FDA), and it i...
Savara Appoints Braden Parker as Chief Commercial Officer, Effective I...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the appointment of Braden Parker as Chief Commercial Officer, effective immediately. Mr. Parker is a seasoned global commercial leader with more than 25 years of experience in the healthcare and biotech industry. Throughout his career, he has developed and executed global commercial plans, including market expansion activities, built high-performance teams, and launched multiple successful rare disease products. Mr. Parker is responsi...
Savara to Host Analyst and Investor Webinar on September 30, 2024
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, will host an analyst and investor webinar on September 30, 2024 from 8:30-9:30 a.m. ET to present data from the Phase 3 IMPALA-2 clinical trial of molgramostim inhalation solution (molgramostim) in autoimmune Pulmonary Alveolar Proteinosis (aPAP) and provide updates on the global commercial landscape and the Company’s market development work. The webinar will feature presentations from Savara's management team and the following key opinion leaders: ...
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgr...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that new data from the Phase 3 IMPALA-2 clinical trial of molgramostim in patients with autoimmune Pulmonary Alveolar Proteinosis (aPAP) were presented at the European Respiratory Society (ERS) Congress 2024 in Vienna, Austria. The poster from this presentation can be found . As previously , the IMPALA-2 trial met its primary endpoint, achieving statistical significance in change from baseline in hemoglobin-adjusted percent predicte...
Savara Announces New Employment Inducement Grant
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On September 5, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to a new employee who recently joined the Company. The inducement awards consist of options to purchase 20,000 shares of the Company’s common stock and restricted stock units (RSUs) covering 20,000 shares of the Company’s common stock. These equity awards were granted under the Savara Inc....
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.